Comments on: Reboxetin (Edronax, Vestra) has little benefit in depression treatment : IQWiG http://www.dancewithshadows.com/pillscribe/reboxetin-edronax-vestra-has-little-benefit-in-depression-treatment-iqwig/ The best of pharma news and views Wed, 28 Jul 2010 09:17:36 +0000 hourly 1 http://wordpress.org/?v=3.1 By: Dan Jule http://www.dancewithshadows.com/pillscribe/reboxetin-edronax-vestra-has-little-benefit-in-depression-treatment-iqwig/comment-page-1/#comment-2620 Dan Jule Thu, 10 Dec 2009 04:22:35 +0000 http://www.dancewithshadows.com/pillscribe/?p=1915#comment-2620 Ridiculous. Reboxetine's antidepressant action is proven in many trials. To say that Reboxetine, an NRI, has no such effect is to say that none of the SNRI drugs have any effect related to the well established influence of NE on mood. Go to any journal database like Medline and examine the research results. This kind of pseudo meta-analysis does not stand. Two studies below are but a small fraction of the overwhelming evidence for reboxetine's effectiveness as an antidepressant. The efficacy of reboxetine as an antidepressant, a meta-analysis of both continuous (mean HAM-D score) and dichotomous (response rate) outcomes. Kobe J Med Sci. 2008; 54(2):E147-58 (ISSN: 1883-0498) Efficacy and tolerability of reboxetine compared with citalopram: a double-blind study in patients with major depressive disorder. J Clin Psychopharmacol. 2006; 26(2):121-7 (ISSN: 0271-0749) Ridiculous. Reboxetine’s antidepressant action is proven in many trials. To say that Reboxetine, an NRI, has no such effect is to say that none of the SNRI drugs have any effect related to the well established influence of NE on mood.

Go to any journal database like Medline and examine the research results. This kind of pseudo meta-analysis does not stand.

Two studies below are but a small fraction of the overwhelming evidence for reboxetine’s effectiveness as an antidepressant.

The efficacy of reboxetine as an antidepressant, a meta-analysis of both continuous (mean HAM-D score) and dichotomous (response rate) outcomes.
Kobe J Med Sci. 2008; 54(2):E147-58 (ISSN: 1883-0498)

Efficacy and tolerability of reboxetine compared with citalopram: a double-blind study in patients with major depressive disorder.
J Clin Psychopharmacol. 2006; 26(2):121-7 (ISSN: 0271-0749)

]]>